Ethihad, Air Arabia, Gulf Air among 15 airlines likely to operate from Kannur

Mangalore, May 30: The first chartered flight to the city of Mangalore, Karnataka in South India is scheduled to depart from the Ras Al Khaimah airport of UAE on June 1.

The SpiceJet flight, chartered by Praveen Shetty, chairman of the Fortune Group of Hotels and president of the Karnataka non-Resident Indian Forum (KNRI), will repatriate 105 staff members of the hotel group, who have been placed on leave, according to a statement issued here on Saturday.

Consul General of India to Dubai Vipul confirmed the reports and said the flight, which will depart at 0945 hrs, will carry home a total of 180 passengers.

Mysuru, May 15: The Temple Town of Nanjangud was till now treated as one unit or a Cluster Containment Zone and was put under complete lock-down as per the containment protocol listed under COVID-19 regulations and Disaster Management Act, 2005.

However on Friday, some of the restrictions have been lifted by Mysuru Deputy Commissioner Abhiram G Sankar who permitted certain activities as no fresh positive cases were reported from the cluster area. The Cluster Containment Zone was declared on March 29 following one employee of Nanjangud-based Jubilant Generics tested positive for the killer Coronavirus. As there were chances of the positive person spreading the disease to other employees of the factory, the cluster rules were enforced. Moreover, there were over 1,000 employees in the Pharma Company and a majority of them lived in and around Nanjangud.

The declaration of Cluster Containment Zone with complete lock-down and quarantining of all the Pharma Company employees proved a success to the District Administration as whoever tested positive – over 73 were later tested positive — had already been quarantined and the dangerous community spread phase was successfully prevented. To a major extent, the Corona virus curve has been flattened. As such, restrictions have been relaxed a bit on Friday.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.